Get the Stockscreener App
5.67
0.26%
-0.015
After Hours:
5.69
0.02
+0.35%
Ardelyx Inc stock is traded at $5.67, with a volume of 3.37M.
It is down -0.26% in the last 24 hours and down -8.99% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$5.685
Open:
$5.74
24h Volume:
3.37M
Relative Volume:
0.96
Market Cap:
$1.40B
Revenue:
$427.68M
Net Income/Loss:
$-58.06M
P/E Ratio:
-23.80
EPS:
-0.2382
Net Cash Flow:
$-37.50M
1W Performance:
+1.25%
1M Performance:
-8.99%
6M Performance:
-5.50%
1Y Performance:
+54.92%
1-Day Range:
$5.575
$5.87
1-Week Range:
$5.535
$5.91
52-Week Range:
$3.49
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.67 | 1.40B | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
ARDX (NASDAQ) insider sales: 125,000 shares notice; Raab 10b5-1 trades listed - Stock Titan
ARDX edges up after hours on IBSRELA momentum and profitability 'right around the corner' - MSN
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility - Yahoo Finance
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
Ardelyx eyes $500M+ revenue as IBSRELA growth puts profitability within reach - MSN
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Hyperphosphatemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharma - Barchart
ARDX Q1 2026 Earnings: Earnings Miss But Stock Gains as Investors Focus on Pipeline ProgressHigh Estimate Range - newsline.com
ARDX Q1 2026 Earnings: EPS Misses Estimates Slightly, Stock Gains Amid Mixed SignalsEarnings Revision Report - newsline.com
· SEC Filing - MLQ.ai
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Pullback And Growth Expectations - simplywall.st
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - TMX Newsfile
Ardelyx Advances Long-Term Tenapanor Trial in Chronic Constipation: What Investors Should Watch - TipRanks
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach - TradingView
ARDX: IBSRELA and XPHOZAH are set for robust growth, targeting $1B and $750M revenues by 2029 - TradingView
IBSRELA-Fueled Q1 Surge and AI Spotlight Could Be A Game Changer For Ardelyx (ARDX) - simplywall.st
ARDX Technical Analysis & Stock Price Forecast - Intellectia AI
Should You Buy Ardelyx (ARDX)? - Insider Monkey
What Triggered Ardelyx's Post-Earnings Plunge - Kavout
Ardelyx Inc. (ARDX) Q1 2026 Earnings: EPS Misses Estimates, but Stock Edges Higher Amid Strategic MomentumProduct Revenue Analysis - newsline.com
This Insider Has Just Sold Shares In Ardelyx - simplywall.st
Ardelyx Inc Live Share Prices and Trades. ARDX.US Live Streaming Share Prices. - London South East
Ardelyx (ARDX) price target increased by 12.82% to 13.46 - MSN
ARDX Q1 2026 Earnings: EPS Misses Estimates Amid Quiet Revenue DisclosureEarnings Surprise Score - newsline.com
Ardelyx chief patient officer sells $43,803 in shares By Investing.com - Investing.com Canada
Ardelyx chief patient officer sells $43,803 in shares - Investing.com
Tax-related Ardelyx (ARDX) insider sale covers RSU withholding needs - Stock Titan
Ardelyx (ARDX) CFO executes 1,455-share tax sell-to-cover after RSU vest - Stock Titan
Ardelyx (ARDX) officer’s RSU vesting triggers 2,306-share tax sell - Stock Titan
Ardelyx (ARDX) HR chief sells 1,846 shares to cover RSU taxes - Stock Titan
Ardelyx (ARDX) Chief Commercial Officer sells 7,998 shares to cover RSU taxes - Stock Titan
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ardelyx Inc Stock (ARDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reilly Joseph James | See Remarks |
May 21 '26 |
Sale |
6.27 |
3,719 |
23,309 |
149,107 |
| Hohenleitner Susan | Chief Financial Officer |
May 21 '26 |
Sale |
6.27 |
1,455 |
9,119 |
229,078 |
| Bishop John E | See Remarks |
May 21 '26 |
Sale |
6.27 |
2,306 |
14,453 |
336,845 |
| Brady James Parker | Chief Human Resources Officer |
May 21 '26 |
Sale |
6.27 |
1,846 |
11,570 |
261,066 |
| Foster Eric Duane | Chief Commercial Officer |
May 21 '26 |
Sale |
6.27 |
7,998 |
50,127 |
417,972 |
| Kelliher Mike | Chief Business Officer |
May 21 '26 |
Sale |
6.27 |
7,248 |
45,427 |
357,418 |
| Williams Laura A | Chief Patient Officer |
May 21 '26 |
Sale |
6.27 |
6,989 |
43,804 |
429,093 |
| RAAB MICHAEL | President & CEO |
May 21 '26 |
Sale |
6.27 |
54,748 |
343,133 |
1,720,033 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):